Intravenous Immunoglobulin Therapy for Autoantibody-Positive Cerebellar Ataxia
Intravenous Immunoglobulin Therapy for Autoantibody-Positive Cerebellar Ataxia
复制标题
DOI:
10.2169/internalmedicine.48.1802
复制
发表时间:
2009-01-01
影响因子:
1.2
通讯作者:
Koizumi, Kiyoshi
中科院分区:
文献类型:
--
作者:
Nanri, Kazunori;Okita, Mitsunori;Koizumi, Kiyoshi
Objective It has been reported that autoimmune cerebellar ataxias, such as anti-glutamic acid decarboxylase (GAD)-antibody-positive cerebellar ataxia and gluten ataxia, are treatable. Here, we examined the therapeutic efficacy of intravenous immunoglobulin (IVIg) on autoantibody-positive cerebellar ataxia.Patients and Methods IVIg therapy was administered in seven autoantibody-positive cerebellar ataxia patients. Therapeutic efficacy was examined in terms of its effects on clinical symptoms and changes in brain perfusion using single photon emission computed tomography (SPECT).Results Treatment was effective in four cerebellar cortical atrophy patients (two anti-GAD antibody-positive and two anti-gliadin antibody-positive) and in one anti-thyroid antibody-positive spinocerebellar ataxia type 3 (SCA3) patient, but not in two multiple system atrophy (MSA) patients. All four IVIg effective patients who underwent SPECT showed apparent increases in cerebellar perfusion.Conclusion If cerebellar ataxia with an autoimmune mechanism is suspected and radiological findings do not reveal MSA, it is worth considering immunotherapy including IVIg.